Bevacizumab Biosimilar Approval China: NMPA Greenlights First Biosimilar

The National Medical Products Administration (NMPA) in China has granted its first NMPA bevacizumab approval for a biosimilar version of bevacizumab, a monoclonal antibody targeting VEGF. This approval is poised to broaden access to cancer treatment options within the APAC region, marking a significant advancement in the Chinese biosimilar regulatory landscape and potentially reducing treatment costs for patients.

Drug Overview

Bevacizumab (brand name not provided) is a monoclonal antibody that functions by inhibiting vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis. By binding to VEGF-A, bevacizumab prevents it from activating VEGF receptors on endothelial cells, thereby inhibiting the formation of new blood vessels essential for tumor growth. It is primarily indicated for treating various solid tumors, including colorectal, lung, breast, and renal cancers.

IntelligenceRegulatory Impact▾

NMPA are the agencies to watch. Regulatory relevance reads medium for oncology, with bevacizumab most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Insights

Clinical development of bevacizumab biosimilars involves comprehensive analytical, pharmacokinetic, and clinical efficacy studies to demonstrate similarity to the originator product. These studies, including Phase I and Phase III trials, aim to confirm that there are no clinically meaningful differences in safety, purity, or potency between the biosimilar and the reference biologic. The primary endpoint in these trials is typically progression-free survival or overall response rate. Class-typical adverse events include hypertension, proteinuria, bleeding, thromboembolic events, and impaired wound healing. The safety profiles are expected to be consistent with the reference product, with no new safety signals identified.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Context

The NMPA follows a stepwise approval pathway for biosimilars, including comprehensive analytical characterization, nonclinical studies, and clinical trials demonstrating biosimilarity. The process may take several years, with accelerated pathways available for products addressing unmet medical needs. Post-approval pharmacovigilance is required to monitor long-term safety.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for oncology pricing, access, and launch sequencing.

Market Impact

The NMPA approval of a bevacizumab biosimilar introduces competition to the bevacizumab market in China, likely driving down costs and expanding patient access amid rising cancer incidence. This approval intensifies biosimilar competition in APAC and offers a cost-effective alternative to the originator bevacizumab with comparable efficacy and safety, supporting broader patient access in China. The target population includes patients with various solid tumors including colorectal, non-small cell lung, renal cell, and breast cancers, representing a large and growing cancer patient population in China with increasing healthcare expenditure.

IntelligenceStrategic Takeaways▾

The NMPA has approved the first biosimilar of Bevacizumab, a groundbreaking step for cancer treatment accessibility in China.

Future Outlook

The approval of this bevacizumab biosimilar may pave the way for future label expansions to cover all indications of the reference product. The competitive landscape will likely evolve as more domestic and international biosimilar manufacturers enter the Chinese market.

Frequently Asked Questions

References

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• bevacizumab

Related coverage

• NMPA China FDA Drug Approval: 2026 Pathways, Timelines & Impact
• NMPA Drug Approvals Surge in 2025: Record 61 First Global Approvals Signal Accelerated Market Access
• TGA Australia drug approval pharmaceutical: what the regulator is